Chain Biotechnology Limited
Private Limited Company · London
Creditors Voluntary Liquidation (CVL)United KingdomIncorporated 2014Private Limited Company
Documents & history
Available account evidence and business events. This is not a complete filing history or document library.
Accounts to 2024-12-31
IXBRL · 195 source facts · 26 selected values
Validation findingsXBRL valid
Accounts to 2024-12-31
IXBRL · 195 source facts · 26 selected values
Validation findings
XBRL valid
- Reporting period
- 2024-01-01 to 2024-12-31
- Extraction status
- complete
- Numeric facts
- 144
- Documents processed
- 1
- XBRL standards validation
- valid
- Filing-profile validation
- invalid
- Parser
- arelle 2.44.4
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2505_08841562_20241231
- Source archive
- Accounts_Monthly_Data-May2025.zip
Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.
Accounts to 2023-12-31
IXBRL · 195 source facts · 25 selected values
Not assessedlegacy record
Accounts to 2023-12-31
IXBRL · 195 source facts · 25 selected values
Not assessed
legacy record
- Reporting period
- 2023-01-01 to 2023-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 145
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2023-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_2466_08841562_20231231
- Source archive
- Accounts_Monthly_Data-August2024.zip
Accounts to 2022-12-31
IXBRL · 195 source facts · 25 selected values
Not assessedlegacy record
Accounts to 2022-12-31
IXBRL · 195 source facts · 25 selected values
Not assessed
legacy record
- Reporting period
- 2022-01-01 to 2022-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 145
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0010_08841562_20221231
- Source archive
- Accounts_Monthly_Data-April2023.zip
Accounts to 2021-12-31
IXBRL · 203 source facts · 25 selected values
Not assessedlegacy record
Accounts to 2021-12-31
IXBRL · 203 source facts · 25 selected values
Not assessed
legacy record
- Reporting period
- 2021-01-01 to 2021-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 157
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2021-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0105_08841562_20211231
- Source archive
- Accounts_Monthly_Data-April2022.zip
Accounts to 2020-12-31
IXBRL · 173 source facts · 23 selected values
Not assessedlegacy record
Accounts to 2020-12-31
IXBRL · 173 source facts · 23 selected values
Not assessed
legacy record
- Reporting period
- 2020-01-01 to 2020-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 128
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0089_08841562_20201231
- Source archive
- Accounts_Monthly_Data-April2021.zip
Accounts to 2019-12-31
IXBRL · 199 source facts · 23 selected values
Not assessedlegacy record
Accounts to 2019-12-31
IXBRL · 199 source facts · 23 selected values
Not assessed
legacy record
- Reporting period
- 2019-01-01 to 2019-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 155
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2019-01-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0076_08841562_20191231
- Source archive
- Accounts_Monthly_Data-March2020.zip
Accounts to 2018-12-31
IXBRL · 180 source facts · 23 selected values
Not assessedlegacy record
Accounts to 2018-12-31
IXBRL · 180 source facts · 23 selected values
Not assessed
legacy record
- Reporting period
- 2018-01-01 to 2018-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 139
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2014-09-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0066_08841562_20181231
- Source archive
- Accounts_Monthly_Data-May2019.zip
Accounts to 2017-12-31
IXBRL · 135 source facts · 20 selected values
Not assessedlegacy record
Accounts to 2017-12-31
IXBRL · 135 source facts · 20 selected values
Not assessed
legacy record
- Reporting period
- 2017-01-01 to 2017-12-31
- Extraction status
- Legacy / not assessed
- Numeric facts
- 93
- Documents processed
- Not recorded
- XBRL standards validation
- Not assessed
- Filing-profile validation
- Not assessed
- Parser
- Legacy parser
- Taxonomy
- FRS-102-2014-09-01.xsd
- Currency
- GBP
- Source identifier
- Prod224_0052_08841562_20171231
- Source archive
- Accounts_Monthly_Data-March2018.zip
Registered details
08841562- Status
- Liquidation
- Type
- Private Limited Company
- Incorporated
- 2014-01-13
- Jurisdiction
- —
- Registered office
- FORVIS MAZARS LLP, 30 OLD BAILEY, LONDON, EC4M 7AU
Classification
1 SIC codes23112
Capital & company events
Reconstructed equity rounds and matched research funding.
Equity fundraising
4 SH01-derived rounds2024-11-15
£499,747 raised
£1,846,526 estimated post-money
2023-06-02
£1,350,092 raised
£3,620,033 estimated post-money
2022-09-22
£500,002 raised
£5,000,002 estimated post-money
2018-09-10
£144,992 raised
£6,979,584 estimated post-money
Research and innovation
19 matched grantsBridging the oral vaccine efficacy gap for childhood diarrhoeal diseaseLeadInnovate UK · Collaborative R&D · 2022-05-01 – 2024-10-31 · with 1 other participant£276,973awarded
Bridging the oral vaccine efficacy gap for childhood diarrhoeal diseaseLead
Innovate UK · Collaborative R&D · 2022-05-01 – 2024-10-31 · with 1 other participant
£276,973
awarded
Chain Biotechnology Limitedlead£276,973
University of Oxford£199,919
Bioproduction of a high-value synthetic ketone ester and its precursors for a UK-based value and supply chainBBSRC · Research Grant · 2021-02-15 – 2024-02-14 · with 1 other participant£229,858whole project
Bioproduction of a high-value synthetic ketone ester and its precursors for a UK-based value and supply chain
BBSRC · Research Grant · 2021-02-15 – 2024-02-14 · with 1 other participant
£229,858
whole project
University Of NottinghamleadChain Biotechnology Ltd
Advanced Vaccine Delivery to the GutLead
Innovate UK · Collaborative R&D · 2019-12-01 – 2022-02-28
£209,950
awarded
University of Reading and CHAIN Biotechnology LimitedInnovate UK · Knowledge Transfer Partnership · 2019-10-01 – 2021-12-31 · with 1 other participant
University of Reading and CHAIN Biotechnology Limited
Innovate UK · Knowledge Transfer Partnership · 2019-10-01 – 2021-12-31 · with 1 other participant
Chain Biotechnology Limited—
Engineering bacterial therapeutics with enhanced metabolic propertiesBBSRC · Studentship · 2019-09-30 – 2025-09-29 · with 1 other participant£0whole project
Engineering bacterial therapeutics with enhanced metabolic properties
BBSRC · Studentship · 2019-09-30 – 2025-09-29 · with 1 other participant
£0
whole project
University of LeedsleadChain Biotechnology Ltd
Potential therapeutic effects of engineered Clostridium STp products on immune activityMRC · Studentship · 2019-09-30 – 2023-03-30 · with 1 other participant£0whole project
Potential therapeutic effects of engineered Clostridium STp products on immune activity
MRC · Studentship · 2019-09-30 – 2023-03-30 · with 1 other participant
£0
whole project
Imperial College LondonleadChain Biotechnology Ltd
Mucosal delivery of Clostridium spores encoding recombinant overlapping peptides of HPV antigen as therapeutic vaccines for cervical cancerLeadInnovate UK · Feasibility Studies · 2019-04-01 – 2020-09-30 · with 1 other participant£70,000awarded
Mucosal delivery of Clostridium spores encoding recombinant overlapping peptides of HPV antigen as therapeutic vaccines for cervical cancerLead
Innovate UK · Feasibility Studies · 2019-04-01 – 2020-09-30 · with 1 other participant
£70,000
awarded
University of Oxford£80,000
Chain Biotechnology Limitedlead£70,000
MICRoMED – Microbial Restoration of intestinal Metabolite balance for type 2 Diabetes 11915 "The microbial population in the gut and the metabolites it produces play an important role in health. Metabolites have a significant signalling roleLead
Innovate UK · Feasibility Studies · 2018-12-01 – 2019-11-30
£69,976
awarded
Anaerobic Bacterial Spore Therapeutics and their ManufactureLeadInnovate UK · Feasibility Studies · 2018-02-01 – 2018-10-31 · with 2 other participants£37,126awarded
Anaerobic Bacterial Spore Therapeutics and their ManufactureLead
Innovate UK · Feasibility Studies · 2018-02-01 – 2018-10-31 · with 2 other participants
£37,126
awarded
Anaerobic Bacterial Spore Therapeutics and their ManufactureLeadISCF · Feasibility Studies · 2018-02-01 – 2018-10-31 · with 2 other participants£62,464whole project
Anaerobic Bacterial Spore Therapeutics and their ManufactureLead
ISCF · Feasibility Studies · 2018-02-01 – 2018-10-31 · with 2 other participants
£62,464
whole project
Anaerobic Bacterial Spore Therapeutics and their ManufactureISCF · Feasibility Studies · 2018-02-01 – 2018-10-31 · with 2 other participants£62,464whole project
Anaerobic Bacterial Spore Therapeutics and their Manufacture
ISCF · Feasibility Studies · 2018-02-01 – 2018-10-31 · with 2 other participants
£62,464
whole project
Developing Clostridium as a Novel Secretion System for Therapeutic PeptidesLeadInnovate UK · Collaborative R&D · 2017-09-01 – 2019-08-31 · with 1 other participant£353,193awarded
Developing Clostridium as a Novel Secretion System for Therapeutic PeptidesLead
Innovate UK · Collaborative R&D · 2017-09-01 – 2019-08-31 · with 1 other participant
£353,193
awarded
Chain Biotechnology Limitedlead£353,193
University of Nottingham£200,728
Butanediol Production in ClostridiaLead
Innovate UK · Feasibility Studies · 2017-08-01 – 2018-03-31
£106,712
awarded
Butanediol Production in ClostridiaLead
ISCF · Feasibility Studies · 2017-07-31 – 2018-03-30
£106,712
whole project
Butanediol Production in Clostridia
ISCF · Feasibility Studies · 2017-07-31 – 2018-03-30
£106,712
whole project
MaxBio - Maximizing Conversion Yields in BiorefiningBBSRC · Research Grant · 2016-08-31 – 2022-08-30 · with 7 other participants£1,251,187whole project
MaxBio - Maximizing Conversion Yields in Biorefining
BBSRC · Research Grant · 2016-08-31 – 2022-08-30 · with 7 other participants
£1,251,187
whole project
University Of DundeeleadBiocleave LimitedChain Biotechnology LtdJames Hutton LimitedReBio Technologies Limited (UK)University of QueenslandUniversity Of YorkVietnam Academy of Agricultural Science
Engineering Bacteria to Convert Methane into Poly Unsaturated Fatty Acids (PUFA)LeadInnovate UK · Feasibility Studies · 2016-04-01 – 2017-03-31 · with 1 other participant£87,861awarded
Engineering Bacteria to Convert Methane into Poly Unsaturated Fatty Acids (PUFA)Lead
Innovate UK · Feasibility Studies · 2016-04-01 – 2017-03-31 · with 1 other participant
£87,861
awarded
Chain Biotechnology Limitedlead£87,861
University of Nottingham£0
Chiral Chemical Synthesis in ClostridiaLead
Innovate UK · Feasibility Studies · 2015-08-01 – 2016-07-31
£180,737
awarded
Redesigning Metabolic Circuits for Speciality Chemical ProductionLead
Innovate UK · Feasibility Studies · 2015-06-01 – 2015-09-30
£23,100
awarded